Ingen internetforbindelse — viser den gemte version af siden.

Arrowhead Pharmac…

USUSD
← Til Screeneren

Arrowhead Pharmaceuticals Inc (LSE:0HI3) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
arrowheadpharma.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Hovedkontor
Pasadena, United States
Administrerende Direktør
Christopher R. Anzalone
Ansatte
711
Grundlagt
2004
Udestående Aktier
141.25 mio. pr. 2026-07-30
Free Float
122.45 mio.
Markedsværdi
9.22 mia. USD
Insidere
3.66%
Institutionelle Investorer
85.47%
Branche (SIC)
Pharmaceutical Preparations
ISIN
US04280A1007
LEI
549300O3CSB8T7OZ3D66
FCF
−75.1 mio. USD
Gæld
181 mio. USD
Indtjening og FCF — for de 12 måneder frem til 30.06.2026 (virksomhedens seneste rapport).
NAV
3.30 USD · P/NAV 20.0
Balancedato30.06.2026
Aktiver2.11 mia. USD
− Forpligtelser1.65 mia. USD
= Total Egenkapital466 mio. USD
− Ikke-Kontrollerende Interesser512 t. USD
= NAV (aktiekapital i selskabets aktionærer)466 mio. USD
− Immaterielle Aktiver5.59 mio. USD
= Materiel NAV460 mio. USD
Aktier141 135 000
NAV pr. Aktie3.30 USD
Håndgribelig NAV pr. Aktie3.26 USD
Aktiekurs (0HI3)65.8200 USD
P/NAV19.95
NAV-Historie
BalancedatoNAVNAV pr. Aktie
30.06.2026466 mio. USD3.30 USD
31.03.2026614 mio. USD4.37 USD
31.12.2025568 mio. USD4.14 USD
30.09.2025466 mio. USD3.43 USD
30.06.2025522 mio. USD3.78 USD
31.03.2025683 mio. USD4.95 USD
31.12.202452.6 mio. USD0.42 USD
30.09.2024185 mio. USD1.49 USD
Beskrivelse

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

annonce

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksARWR primærUSD58.5 +0.22%almindelige aktier
LSE London Stock Exchange0HI3 IOBUSD65.82 +0.00%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdagHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Største Ejere

EjerAndelAktierRapportdato
Blackrock Inc.10.53%14.83 mio.2026-06-30
Avoro Capital Advisors L…8.06%11.36 mio.2026-06-30
FMR, LLC5.71%8.04 mio.2026-06-30
Vanguard Portfolio Manag…4.51%6.35 mio.2026-06-30
Vanguard Capital Managem…4.34%6.11 mio.2026-06-30
State Street Corporation4.04%5.69 mio.2026-06-30
iShares Trust-iShares Co…3.5%4.93 mio.2026-08-31
VANGUARD INDEX FUNDS-Van…3.01%4.25 mio.2026-06-30
NORGES BANK2.77%3.9 mio.2026-06-30
Invesco Ltd.2.76%3.88 mio.2026-06-30
ANZALONE CHRISTOPHER RIC…≈2.69%3.79 mio.2026-01-02
Geode Capital Management…2.51%3.53 mio.2026-06-30
Fred Alger Management, L…2.34%3.3 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.07 mio.2026-06-30
Fidelity Mt. Vernon Stre…1.81%2.55 mio.2026-07-31
Invesco Exchange-Traded…1.27%1.79 mio.2026-08-31
VANGUARD INDEX FUNDS-Van…1.26%1.77 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.61 mio.2026-06-30
SPDR SERIES TRUST-State…1.05%1.48 mio.2026-08-31
SPDR S&P MIDCAP 400 ETF…0.73%1.03 mio.2026-08-31
iShares Trust-iShares Bi…0.69%968 7382026-07-31
O'BRIEN PATRICK C (Chief…≈0.39%547 4082026-01-06
MYSZKOWSKI KENNETH ALLEN…≈0.32%455 4332025-01-07
HAMILTON JAMES C (Office…≈0.16%226 9582026-04-23
APEL DANIEL JOSEPH (Chie…≈0.12%162 9052026-04-22
GIVEN DOUGLAS BRUCE (Dir…≈0.09%124 1672024-12-17
PERRY MICHAEL S (Directo…≈0.08%111 4592026-08-18
FERRARI MAURO (Director)≈0.05%69 0532025-12-26
WADDILL WILLIAM D (Direc…≈0.04%56 5632025-12-19
LU HONGBO B (Director)≈0.04%52 0122026-05-12